Integrative toxicogenomics: Advancing precision medicine and toxicology through artificial intelligence and OMICs technology.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published Date:

Abstract

More information about a person's genetic makeup, drug response, multi-omics response, and genomic response is now available leading to a gradual shift towards personalized treatment. Additionally, the promotion of non-animal testing has fueled the computational toxicogenomics as a pivotal part of the next-gen risk assessment paradigm. Artificial Intelligence (AI) has the potential to provid new ways analyzing the patient data and making predictions about treatment outcomes or toxicity. As personalized medicine and toxicogenomics involve huge data processing, AI can expedite this process by providing powerful data processing, analysis, and interpretation algorithms. AI can process and integrate a multitude of data including genome data, patient records, clinical data and identify patterns to derive predictive models anticipating clinical outcomes and assessing the risk of any personalized medicine approaches. In this article, we have studied the current trends and future perspectives in personalized medicine & toxicology, the role of toxicogenomics in connecting the two fields, and the impact of AI on personalized medicine & toxicology. In this work, we also study the key challenges and limitations in personalized medicine, toxicogenomics, and AI in order to fully realize their potential.

Authors

  • Ajay Vikram Singh
    Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), 10589 Berlin, Germany. Electronic address: Ajay-Vikram.Singh@bfr.bund.de.
  • Vaisali Chandrasekar
    Department of Surgery, Hamad Medical Corporation (HMC), Doha 3050, Qatar.
  • Namuna Paudel
    Department of Chemistry, Amrit Campus, Institute of Science and Technology, Tribhuvan University, Lainchaur, Kathmandu 44600 Nepal.
  • Peter Laux
    Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR) , Berlin , Germany.
  • Andreas Luch
    Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR) , Berlin , Germany.
  • Donato Gemmati
    Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy; Centre Hemostasis & Thrombosis, University of Ferrara, 44121 Ferrara, Italy; Centre for Gender Medicine, University of Ferrara, 44121 Ferrara, Italy.
  • Veronica Tisato
    Department of Morphology, Surgery and Experimental Medicine, Section of Anatomy and Histology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
  • Kirti S Prabhu
    Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Shahab Uddin
    Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Sarada Prasad Dakua
    Department of Surgery, Hamad Medical Corporation (HMC), PO Box 3050, Doha, Qatar.